Home / Business and Economy / COO Sells $416K in Rapport Stock
COO Sells $416K in Rapport Stock
13 Jul
Summary
- COO sold 10,000 shares for ~$416,000 on June 30, 2026.
- Sale represents 6.25% of her direct holdings.
- Transaction occurred during a period of significant stock appreciation.
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, engaged in a significant stock sale on June 30, 2026. She sold 10,000 shares of common stock through multiple open-market transactions, realizing approximately $416,000. This sale represents the largest single trade size in her recent selling history, which has consistently involved offloading shares since November 2025.
The disposition reduced Gault's direct ownership in Rapport Therapeutics by 6.25%. Following the sale, she retained 149,914 shares, valued at roughly $5.9 million as of July 1, 2026. This holding constitutes 0.41% of the company's outstanding shares.
This transaction occurred during a period of substantial growth for Rapport Therapeutics, with its stock appreciating 223.67% year-over-year as of July 1, 2026. The sale aligns with a prudent approach to liquidity management, capitalizing on elevated market valuations.
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its lead candidate, RAP-219, targets focal epilepsy and other conditions like pain and hearing impairment.
